This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://localhost/temp/predkladatel/
n9http://linked.opendata.cz/resource/domain/vavai/projekt/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n5http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F07%3A00033158%21RIV10-MSM-14110___/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F07%3A00033158%21RIV10-MSM-14110___
rdf:type
n7:Vysledek skos:Concept
dcterms:description
Objective To evaluate the clinical status and radiographic progression in patients with rheamzatoid arthritis (RA) being followed by the Czech National Registry of biological treatments. Methods Patients who failed at least two disease-modifying antirheumatic drugs and had high disease activity (DAS28 > 5.1) were treated with infliximab. Radiographic progression was measured with a modified version of the Sharp score (TSS) after 54 weeks of treatment. Results Ninety-nine patients with an average disease duration of 13.7 years were enrolled. The DAS28 dropped from 6.66 to 4.07 (p < 0.001). Before treatment the mean TSS was 90.1 and the mean estimated yearly disease progression was 8.56. After 54 weeks of infliximab, radiographic progression was 4.15 times slower than the estimated rate before treatment and 63 patients did not show any radiographic progression at all. In the remaining 36 patients, the progression rate slowed to 3.8 +/- 0.9 from the estimated TSS of 10.9 +/- 6. Objective To evaluate the clinical status and radiographic progression in patients with rheamzatoid arthritis (RA) being followed by the Czech National Registry of biological treatments. Methods Patients who failed at least two disease-modifying antirheumatic drugs and had high disease activity (DAS28 > 5.1) were treated with infliximab. Radiographic progression was measured with a modified version of the Sharp score (TSS) after 54 weeks of treatment. Results Ninety-nine patients with an average disease duration of 13.7 years were enrolled. The DAS28 dropped from 6.66 to 4.07 (p < 0.001). Before treatment the mean TSS was 90.1 and the mean estimated yearly disease progression was 8.56. After 54 weeks of infliximab, radiographic progression was 4.15 times slower than the estimated rate before treatment and 63 patients did not show any radiographic progression at all. In the remaining 36 patients, the progression rate slowed to 3.8 +/- 0.9 from the estimated TSS of 10.9 +/- 6.
dcterms:title
Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment
skos:prefLabel
Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infiiximab treatment
skos:notation
RIV/00216224:14110/07:00033158!RIV10-MSM-14110___
n3:aktivita
n17:P
n3:aktivity
P(1M0571)
n3:cisloPeriodika
4
n3:dodaniDat
n12:2010
n3:domaciTvurceVysledku
n4:4504135 n4:9544615
n3:druhVysledku
n14:J
n3:duvernostUdaju
n11:S
n3:entitaPredkladatele
n5:predkladatel
n3:idSjednocenehoVysledku
446316
n3:idVysledku
RIV/00216224:14110/07:00033158
n3:jazykVysledku
n8:eng
n3:klicovaSlova
rheumatoid arthritis; biological treatment; radiographic progression
n3:klicoveSlovo
n10:radiographic%20progression n10:biological%20treatment n10:rheumatoid%20arthritis
n3:kodStatuVydavatele
IT - Italská republika
n3:kontrolniKodProRIV
[3AEB5F44E7CA]
n3:nazevZdroje
Clinical and Experimental Rheumatology
n3:obor
n18:FP
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
9
n3:projekt
n9:1M0571
n3:rokUplatneniVysledku
n12:2007
n3:svazekPeriodika
25
n3:tvurceVysledku
Pavelka, K. Studynkova, J. T. Svobodník, Adam Jarosova, K. Dušek, Ladislav Svihalek, J. Tegzova, D. Vencovsky, J. Gatterova, J.
s:issn
0392-856X
s:numberOfPages
5
n16:organizacniJednotka
14110